9 May 2020 - Chinese regulators have approved Novartis' Mayzent to treat relapsing multiple sclerosis in adults, the Swiss drug maker said in a statement on Saturday.
Other drugs approved by China's National Medical Products Administration to treat patients with multiple sclerosis include Novartis' Gilenya, Bayer's Betaferon and Sanofi's Aubagio.